medRxiv:Omicron的重症和死亡率相比Delta大幅下降,死亡风险降低91%

2022-01-14 “生物世界”公众号 “生物世界”公众号

本论文通过对约52000名感染Omicron突变株的人和约17000名感染,与感染Delta相比,感染Omicron的人住院的可能性降低了一半,进ICU的可能性降低了75%,死亡风险降低了91%。

近日,加州大学伯克利分校、南加州Kaiser Permanente医院和美国疾控中心的研究人员在预印本发表论文,通过对约52000名感染Omicron突变株的人和约17000名感染Delta突变株的人进行的分析显示,与感染Delta相比,感染Omicron的人住院的可能性降低了一半,进ICU的可能性降低了75%,死亡风险降低了91%

Omicron感染者的住院时间中位数为1.5 天,而Delta为5天,90%的Omicron感染者在3天或更短的时间内就能出院。这52000名感染Omicron突变株的人,没有一个人最终使用呼吸机,而感染Delta突变株的17000人中有11人使用了呼吸机。

这些分析是根据南加州Kaiser Permanente医院系统的数据进行的,该系统在2021年11月30日至2022年1月1日期间为大约470万人口提供新冠相关服务,在此期间,Delta和Omicron在美国都相当流行。

Attributes of cases with SGTF (Omicron) and non-SGTF (Delta [B.1.617.2]) samples detected

美国疾控中心主任 Rochelle Walensky 表示,这项研究控制了重要的关键参数,例如年龄、性别、先前的新冠感染期刊、疫苗接种和合并症。这项研究结果显示,Omicron本质上不如Delta严重。虽然该研究也显示出疫苗对防止Omicron感染的效果下降,但疫苗对其重症仍然有很好地保护。

Rochelle Walensky 还警告说,虽然这项研究显示Omicron感染后的住院、重症和死亡风险大幅下降,但现在也不应放松警惕,因为Omicron的传染性极强,使得美国现在的医疗系统和医疗工作者不堪重负。

 

目前美国每天有约100万人感染,其中大多数是Omicron,每天有15万人因感染新冠住院,每天有超过1600人因此死亡。

拜登总统首席医疗顾问安东尼·福奇(Anthony Fauci)表示:Omicron凭借其强大的、前所未有的传播效率,最终将感染几乎所有(美国)人。他还表示,当美国摆脱当前的感染浪潮之后,将在未来过渡到与新冠病毒共存的状态,新冠疫苗可以帮助大多数人避免发展为重症,并为那些最脆弱的人提供有效的治疗

原始出处:

Joseph A. Lewnard, Vennis X. Hong, Manish M. Patel, et al. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. medRxiv, 2022. doi: https://doi.org/10.1101/2022.01.11.22269045.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1820743, encodeId=5ade1820e437b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 26 02:20:29 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857994, encodeId=60fc185e9947a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Mar 15 17:20:29 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084687, encodeId=fde2208468e84, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 17 10:20:29 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256170, encodeId=bfea12561e003, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391284, encodeId=1050139128453, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611410, encodeId=639d161141071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184651, encodeId=222c11846514e, content=最好的疫苗:奥米克戎, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/dcaad6fc25914e95961d57709a5ecb54/259c9e990bd742c888414ececefebf52.jpg, createdBy=c1125402802, createdName=chinal**, createdTime=Sat Jan 15 21:01:40 CST 2022, time=2022-01-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1820743, encodeId=5ade1820e437b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 26 02:20:29 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857994, encodeId=60fc185e9947a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Mar 15 17:20:29 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084687, encodeId=fde2208468e84, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 17 10:20:29 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256170, encodeId=bfea12561e003, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391284, encodeId=1050139128453, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611410, encodeId=639d161141071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184651, encodeId=222c11846514e, content=最好的疫苗:奥米克戎, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/dcaad6fc25914e95961d57709a5ecb54/259c9e990bd742c888414ececefebf52.jpg, createdBy=c1125402802, createdName=chinal**, createdTime=Sat Jan 15 21:01:40 CST 2022, time=2022-01-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1820743, encodeId=5ade1820e437b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 26 02:20:29 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857994, encodeId=60fc185e9947a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Mar 15 17:20:29 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084687, encodeId=fde2208468e84, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 17 10:20:29 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256170, encodeId=bfea12561e003, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391284, encodeId=1050139128453, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611410, encodeId=639d161141071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184651, encodeId=222c11846514e, content=最好的疫苗:奥米克戎, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/dcaad6fc25914e95961d57709a5ecb54/259c9e990bd742c888414ececefebf52.jpg, createdBy=c1125402802, createdName=chinal**, createdTime=Sat Jan 15 21:01:40 CST 2022, time=2022-01-15, status=1, ipAttribution=)]
    2022-05-17 xjy02
  4. [GetPortalCommentsPageByObjectIdResponse(id=1820743, encodeId=5ade1820e437b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 26 02:20:29 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857994, encodeId=60fc185e9947a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Mar 15 17:20:29 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084687, encodeId=fde2208468e84, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 17 10:20:29 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256170, encodeId=bfea12561e003, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391284, encodeId=1050139128453, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611410, encodeId=639d161141071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184651, encodeId=222c11846514e, content=最好的疫苗:奥米克戎, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/dcaad6fc25914e95961d57709a5ecb54/259c9e990bd742c888414ececefebf52.jpg, createdBy=c1125402802, createdName=chinal**, createdTime=Sat Jan 15 21:01:40 CST 2022, time=2022-01-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1820743, encodeId=5ade1820e437b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 26 02:20:29 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857994, encodeId=60fc185e9947a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Mar 15 17:20:29 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084687, encodeId=fde2208468e84, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 17 10:20:29 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256170, encodeId=bfea12561e003, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391284, encodeId=1050139128453, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611410, encodeId=639d161141071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184651, encodeId=222c11846514e, content=最好的疫苗:奥米克戎, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/dcaad6fc25914e95961d57709a5ecb54/259c9e990bd742c888414ececefebf52.jpg, createdBy=c1125402802, createdName=chinal**, createdTime=Sat Jan 15 21:01:40 CST 2022, time=2022-01-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1820743, encodeId=5ade1820e437b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 26 02:20:29 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857994, encodeId=60fc185e9947a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Mar 15 17:20:29 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084687, encodeId=fde2208468e84, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 17 10:20:29 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256170, encodeId=bfea12561e003, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391284, encodeId=1050139128453, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611410, encodeId=639d161141071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184651, encodeId=222c11846514e, content=最好的疫苗:奥米克戎, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/dcaad6fc25914e95961d57709a5ecb54/259c9e990bd742c888414ececefebf52.jpg, createdBy=c1125402802, createdName=chinal**, createdTime=Sat Jan 15 21:01:40 CST 2022, time=2022-01-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1820743, encodeId=5ade1820e437b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 26 02:20:29 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857994, encodeId=60fc185e9947a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Mar 15 17:20:29 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084687, encodeId=fde2208468e84, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 17 10:20:29 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256170, encodeId=bfea12561e003, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391284, encodeId=1050139128453, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611410, encodeId=639d161141071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 16 03:20:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184651, encodeId=222c11846514e, content=最好的疫苗:奥米克戎, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/dcaad6fc25914e95961d57709a5ecb54/259c9e990bd742c888414ececefebf52.jpg, createdBy=c1125402802, createdName=chinal**, createdTime=Sat Jan 15 21:01:40 CST 2022, time=2022-01-15, status=1, ipAttribution=)]
    2022-01-15 chinal**

    最好的疫苗:奥米克戎

    0

相关资讯

2022年1月10日简报:天津再新增20例奥密克戎感染;塞浦路斯研究人员称发现“德尔塔+奥密克戎”混合毒株Deltacron;南非仅2个月就渡过疫情高峰

截至北京时间2022年1月10日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过3亿770万例,新增1,767,534例,达到307,699,

2022年1月11日简报:儿童更易感染奥密克戎,容易导致婴幼儿吼哮症;辉瑞CEO称3月底前或推出专门针对奥密克戎的新冠疫苗;印度感染人数创新高

截至北京时间2022年1月11日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过3亿1027万例,新增1,832,693例,达到310,277

2022年1月12日简报:欧洲超一半人口将在未来6至8周感染奥密克戎毒株;奥密克戎在美国占98%,并未出现与Delta共感染;未来所有人都可能感染奥密克戎

截至北京时间2022年1月12日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过3亿1380万例,新增2,661,969例,达到313,800

2022年1月14日简报:天津定点医院收治的50名儿童基本都是无症状和轻症人群;昨日全球新增300万例,欧洲和美国新增病例可能快达峰值

截至北京时间2022年1月14日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过3亿2046万例,新增3,005,672例,达到320,460

2022年1月13日简报:福奇称奥密克戎毒株将在美国感染“几乎每个人”,欧洲药品管理局认为奥密克戎将迅速成为一种地方性疾病,全球日增近300万例

截至北京时间2022年1月13日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过3亿1706万例,新增2,957,791例,达到317,061